California · 2025–26 Regular Session · Assembly Bill
AB 1320: California Affordable Drug Manufacturing Act of 2020: opioid antagonists.
Did not advance Official data
- Introduced
- In committee
- Passed one chamber
- Passed both chambers
- Enacted
- Did not advance
Last official action: ·Record last updated:
Plain-language summary
AB 1320 is a assembly bill introduced in the California Assembly on February 21, 2025. According to its official title, it concerns: California Affordable Drug Manufacturing Act of 2020: opioid antagonists. Primary sponsor: Joe Patterson (R). Most recent recorded action (February 2, 2026): From committee: Filed with the Chief Clerk pursuant to Joint Rule 56.
Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written
Official summary
Legislative Counsel’s Digest (official, as of the latest version). Written by nonpartisan legislative staff; reproduced verbatim.
Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) or its departments to enter into partnerships, in consultation with other state departments as necessary, to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs. For purposes of implementing these provisions, existing law authorizes CHHSA and its departments, including the Department of Health Care Access and Information, to enter into exclusive or nonexclusive contracts on a bid or negotiated bases. Existing law exempts these contracts entered into by CHHSA and its departments from the review or approval of any division of the Department of General Services as well as from provisions pertaining to bidding and awarding of state contracts.
This bill would prohibit a state agency from awarding a contract, pursuant to the above provisions, on a noncompetitive basis for the purchase or acquisition of an opioid antagonist, as defined, with a contractor that has entered into a multistate settlement agreement for its role in contributing to the opioid epidemic. The bill would make a contract void and unenforceable for a violation of this provision and apply those provisions retroactively to contracts entered into before January 1, 2026.
Sponsors
Sponsors by party (alphabetical): Republican 1
| Name | Role | Party | Chamber | District |
|---|---|---|---|---|
| Joe Patterson | Primary sponsor | Republican | Assembly | 5 |
“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.
Recent official actions
- From committee: Filed with the Chief Clerk pursuant to Joint Rule 56.
- Died pursuant to Art. IV, Sec. 10(c) of the Constitution.
- In committee: Set, first hearing. Failed passage. Reconsideration granted.
- Referred to Com. on HEALTH.
- Read first time.
- From printer. May be heard in committee March 24.
- Introduced. To print.